Trust medics calculate ovarian cancer risk
Doctors from Imperial College Healthcare NHS Trust have helped formulated a system that uses ultrasound images to accurately work out the likelihood of an ovarian growth being cancerous.
The team – from international institutions including Imperial College Healthcare NHS Trust and Imperial College London – say the system could allow medics to classify a tumour as cancerous before surgery, and could potentially improve outcomes for patients. In a study looking at the tumours of 4,500 women, the model predicted cancer risk with 98 per cent accuracy.
Ovarian cancer affects approximately 230,000 women globally – around 7,100 in the UK. Women aged over 50 are most commonly affected, and symptoms include abdominal pain and persistent bloating. The disease is diagnosed through a combination of scans and blood tests.
In the new study, which was conducted with over 4,500 patients from across Europe the researchers used an existing system of ovarian tumour classification called the Simple Rules. These act like a checklist for healthcare professionals performing an ultrasound scan of the tumour. They highlight ten features – such as size of the growth or whether it has smooth or rough edges – and classify it into one of three categories: cancerous, non-cancerous (benign) or inconclusive. This helps medics decide whether or not to operate.
The team behind the current study wanted to see if the Simple Rules system could be made more detailed – and identify the percentage cancer risk for each individual patient. They also wanted to reduce the number of tumours dubbed inconclusive.
After analysing the tumours of over 4,500 women over the course of ten years, the team created a mathematical model that weights each of the features in the Simple Rules, and calculates the risk of a tumour being cancerous.
The study, published in the American Journal of Obstetrics and Gynecology, found the model predicted cancer risk with 98 per cent accuracy. The system maintained its accuracy even without using results from the blood test currently used to help diagnose the condition, called CA125.
Professor Tom Bourne, one of the senior authors on the study and a consultant at the Trust said:
“This system enables us to accurately calculate a cancer risk for each individual patient with ovarian growths, before they undergo surgery. Using this information we can then discuss with patients the best course of treatment.”
Notes to editors
1. "Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis (IOTA) group,” by Dirk Timmerman, MD et al is published in the American Journal of Obstetrics and Gynecology (DOI: http://dx.doi.org/10.1016/j.ajog.2016.01.007).